[
    [
        {
            "time": "",
            "orginal_text": "年报披露即将，擦亮双眼提前甄选业绩真增长公司",
            "features": {
                "keywords": [
                    "年报",
                    "业绩增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "年报披露即将，擦亮双眼提前甄选业绩真增长公司",
            "scores": {
                "News_content": "年报披露即将，擦亮双眼提前甄选业绩真增长公司",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业1月月报：把握年底估值切换行情布局2018",
            "features": {
                "keywords": [
                    "医药生物",
                    "估值切换",
                    "布局2018"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药生物行业1月月报：把握年底估值切换行情布局2018",
            "scores": {
                "News_content": "医药生物行业1月月报：把握年底估值切换行情布局2018",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "恒瑞医药最新消息：BTK抑制剂授权TGTtherapeutics 走出去战略加速",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "BTK抑制剂",
                    "走出去战略"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "恒瑞医药最新消息：BTK抑制剂授权TGTtherapeutics 走出去战略加速",
            "scores": {
                "News_content": "恒瑞医药最新消息：BTK抑制剂授权TGTtherapeutics 走出去战略加速",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "中国平安、京东方A、美的集团入选2018“下注中国”十大核心资产",
            "features": {
                "keywords": [
                    "中国平安",
                    "京东方A",
                    "美的集团",
                    "核心资产"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "科技",
                    "家电"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "中国平安、京东方A、美的集团入选2018“下注中国”十大核心资产",
            "scores": {
                "News_content": "中国平安、京东方A、美的集团入选2018“下注中国”十大核心资产",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业三大细分市场率先受益(附股)",
            "features": {
                "keywords": [
                    "医药行业",
                    "细分市场",
                    "受益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药行业三大细分市场率先受益(附股)",
            "scores": {
                "News_content": "医药行业三大细分市场率先受益(附股)",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "安信国际 | 石药集团(1093)：收购友芝友股权，拓展生物药领域",
            "features": {
                "keywords": [
                    "石药集团",
                    "收购",
                    "生物药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "安信国际 | 石药集团(1093)：收购友芝友股权，拓展生物药领域",
            "scores": {
                "News_content": "安信国际 | 石药集团(1093)：收购友芝友股权，拓展生物药领域",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "两融余额三连升再创新高 京东方A成融资客首选标的",
            "features": {
                "keywords": [
                    "两融余额",
                    "京东方A",
                    "融资"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "两融余额三连升再创新高 京东方A成融资客首选标的",
            "scores": {
                "News_content": "两融余额三连升再创新高 京东方A成融资客首选标的",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "康美药业连发五公告，斥资超10亿元寓意几何？",
            "features": {
                "keywords": [
                    "康美药业",
                    "公告",
                    "斥资"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "康美药业连发五公告，斥资超10亿元寓意几何？",
            "scores": {
                "News_content": "康美药业连发五公告，斥资超10亿元寓意几何？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "2017年中国药企获批准的ANDA",
            "features": {
                "keywords": [
                    "药企",
                    "ANDA",
                    "批准"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "2017年中国药企获批准的ANDA",
            "scores": {
                "News_content": "2017年中国药企获批准的ANDA",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "【陆股通交易追踪】陆港通净买入 银行股获青睐 茅台等白酒股遭减持",
            "features": {
                "keywords": [
                    "陆港通",
                    "银行股",
                    "白酒股",
                    "减持"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "original_text": "【陆股通交易追踪】陆港通净买入 银行股获青睐 茅台等白酒股遭减持",
            "scores": {
                "News_content": "【陆股通交易追踪】陆港通净买入 银行股获青睐 茅台等白酒股遭减持",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "【医药】恒瑞医药(600276): BTK抑制剂海外授权，创新药全球化布局更进一步",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "BTK抑制剂",
                    "海外授权",
                    "全球化布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【医药】恒瑞医药(600276): BTK抑制剂海外授权，创新药全球化布局更进一步",
            "scores": {
                "News_content": "【医药】恒瑞医药(600276): BTK抑制剂海外授权，创新药全球化布局更进一步",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "恒瑞医药：第七届董事会第十八次会议决议公告",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "董事会决议"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "恒瑞医药：第七届董事会第十八次会议决议公告",
            "scores": {
                "News_content": "恒瑞医药：第七届董事会第十八次会议决议公告",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "英媒：恒瑞医药向美TG公司授权新药研发许可",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "新药研发",
                    "授权"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "英媒：恒瑞医药向美TG公司授权新药研发许可",
            "scores": {
                "News_content": "英媒：恒瑞医药向美TG公司授权新药研发许可",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]